中药行业利好加持，盘龙药业大涨超6%

Industry Overview - The Chinese traditional medicine sector is experiencing performance pressure due to weak sales in pharmacies and hospitals since 2025, leading to a divergence in the performance of listed companies [3] - OTC leading enterprises show strong performance resilience, while the industry is undergoing a painful transition in its development model amid healthcare reform [3] - Future success will depend on diversified channels, strong brand power, and high clinical value, with long-term policies guiding the industry towards high-quality and standardized development [3] - The market for traditional Chinese medicine is rapidly growing, with new products driving growth momentum [3] - Continuous favorable measures from the supply, payment, and demand sides are promoting the prosperity and development of the traditional Chinese medicine industry [3] Company Overview - Panlong Pharmaceutical, a leading enterprise in the field of traditional Chinese medicine for rheumatology and orthopedics, has 25 production lines certified by the new national GMP, producing tablets and capsules [3] - The company has developed a strong product lineup, including the nationally exclusive patented product "Panlong Seven Tablets," covering 12 major functional categories and over 100 specifications [3] - The company is actively expanding its online sales channels for health products across six platforms, including JD.com, Taobao, Weimeng, WeChat Mini Programs, Video Number, and Douyin [4] - Panlong Pharmaceutical is expected to benefit from policy dividends, the accelerating trend of population aging, and consumption upgrades [5]